aTyr Pharma (NASDAQ:ATYR) Sets New 12-Month Low After Analyst Downgrade

aTyr Pharma, Inc. (NASDAQ:ATYR) shares reached a new 52-week low during mid-day trading on Monday after HC Wainwright downgraded the stock from a buy rating to a neutral rating. The company traded as low as $1.00 and last traded at $1.01, with a volume of 153796609 shares trading hands. The stock had previously closed at $6.03.

Other analysts have also recently issued reports about the company. Wells Fargo & Company boosted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, June 20th. Wall Street Zen cut aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Leerink Partners restated a “market perform” rating on shares of aTyr Pharma in a research report on Monday. Cantor Fitzgerald cut aTyr Pharma from an “overweight” rating to a “neutral” rating in a research report on Monday. Finally, Jefferies Financial Group boosted their price objective on aTyr Pharma from $9.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, aTyr Pharma currently has an average rating of “Moderate Buy” and an average target price of $23.25.

Institutional Trading of aTyr Pharma

A number of large investors have recently bought and sold shares of the stock. Octagon Capital Advisors LP grew its position in aTyr Pharma by 7.5% in the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after acquiring an additional 268,000 shares during the period. Geode Capital Management LLC grew its position in aTyr Pharma by 126.1% in the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company’s stock valued at $10,639,000 after acquiring an additional 1,170,276 shares during the period. Woodline Partners LP bought a new stake in aTyr Pharma in the fourth quarter valued at $6,092,000. Millennium Management LLC grew its position in aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company’s stock valued at $4,829,000 after acquiring an additional 1,231,052 shares during the period. Finally, Ally Bridge Group NY LLC boosted its stake in aTyr Pharma by 11.0% in the first quarter. Ally Bridge Group NY LLC now owns 777,020 shares of the company’s stock worth $2,347,000 after purchasing an additional 77,290 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Trading Down 83.3%

The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The company has a market cap of $98.97 million, a price-to-earnings ratio of -1.26 and a beta of 1.01. The business has a 50 day simple moving average of $5.28 and a 200 day simple moving average of $4.37.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). As a group, equities analysts forecast that aTyr Pharma, Inc. will post -0.91 EPS for the current year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.